Patents by Inventor Eric Martin VAUGHN

Eric Martin VAUGHN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200237894
    Abstract: The present invention relates to an immunogen-carrier, wherein the immunogen-carrier is preferably a virus-like particle (VLP) composed of a plurality of a modified PCV2 ORF2 protein. In particular, the present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a compliance marker for vaccines including a subunit antigen, and a DIVA (Differentiating Infected from Vaccinated Animals) system which makes it possible to differentiate between animals infected with a pathogen and animals treated with a subunit antigen derived from said pathogen.
    Type: Application
    Filed: January 22, 2020
    Publication date: July 30, 2020
    Inventors: Luis Alejandro HERNANDEZ, Eric Martin VAUGHN
  • Patent number: 10702601
    Abstract: The present invention relates to immunogenic compositions, wherein the immunogenic compositions include a recombinant spike antigen porcine epidemic diarrhea virus (PEDV). The immunogenic compositions commonly include an oil-in-water emulsion as an adjuvant. Methods for producing the immunogenic compositions and the recombinant PEDV spike antigen are also provided.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 7, 2020
    Inventors: Luis Alejandro Hernandez, Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria
  • Patent number: 10668144
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 2, 2020
    Inventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
  • Patent number: 10660952
    Abstract: The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 26, 2020
    Inventors: Troy James Kaiser, Jeremy Kroll, Eric Martin Vaughn
  • Patent number: 10555994
    Abstract: The present invention relates to an immunogen-carrier, wherein the immunogen-carrier is preferably a virus-like particle (VLP) composed of a plurality of a modified PCV2 ORF2 protein. In particular, the present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a compliance marker for vaccines including a subunit antigen, and a DIVA (Differentiating Infected from Vaccinated Animals) system which makes it possible to differentiate between animals infected with a pathogen and animals treated with a subunit antigen derived from said pathogen.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: February 11, 2020
    Inventors: Luis Alejandro Hernandez, Eric Martin Vaughn
  • Publication number: 20200038504
    Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with corona virus infection including porcine epidemic diarrhea virus (PEDV) and/or porcine deltacorona virus (PDCoV). The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen, and/or an adjuvant inactivated/killed PDCoV (e.g., chemically inactivated PDCoV virus), and/or recombinant PDCoV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and/or PDCoV and methods of producing the porcine epidemic diarrhea virus and/or porcine deltacorona virus vaccine are also provided.
    Type: Application
    Filed: January 26, 2018
    Publication date: February 6, 2020
    Inventors: Scott ACKERMAN, Joseph Ralph HERMANN, Luis Alejandro HERNANDEZ, Lea Ann HOBBS, Arun V. IYER, Sean O'CONNER, Abby Rea PATTERSON, Eric Martin VAUGHN, Joseph Gilbert VICTORIA
  • Publication number: 20200030438
    Abstract: The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: October 10, 2019
    Publication date: January 30, 2020
    Inventors: Scott Eugene BUCKLIN, Troy James KAISER, Jeremy KROLL, Philip UTLEY, Eric Martin VAUGHN
  • Patent number: 10545148
    Abstract: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: January 28, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Arun V. Iyer, Joseph Ralph Hermann, Michael B. Roof, Eric Martin Vaughn, Merrill Lynn Schaeffer
  • Patent number: 10485866
    Abstract: The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: November 26, 2019
    Inventors: Scott Eugene Bucklin, Troy James Kaiser, Jeremy Kroll, Philip Utley, Eric Martin Vaughn
  • Patent number: 10329586
    Abstract: The present invention relates to the field of CAdV vector vaccines, and especially to promoters suitable to express target antigens from such vector vaccines. Disclosed and claimed are recombinant canine adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector), expression products from them, and uses for the expression products. Additionally, disclosed and claimed are truncated EHV4 promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: June 25, 2019
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Andreas Gallei, Ramesh Koukuntla, Robert Barry Mandell, Alice Mundt, Kristina Rehmet, Eric Martin Vaughn
  • Publication number: 20190154688
    Abstract: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
    Type: Application
    Filed: November 8, 2018
    Publication date: May 23, 2019
    Inventors: Arun V. Iyer, Joseph Ralph Hermann, Michael B. Roof, Eric Martin Vaughn, Merrill Lynn Schaeffer
  • Publication number: 20190134180
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 9, 2019
    Inventors: Kim BURGARD, Jeremy KROLL, Sarah M. LAYTON, Volker OHLINGER, Francois-Xavier ORVEILLON, Stefan PESCH, Michael Dennis PIONTKOWSKI, Michael B. ROOF, Philip UTLEY, Eric Martin VAUGHN
  • Publication number: 20190023747
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Application
    Filed: October 8, 2018
    Publication date: January 24, 2019
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Patent number: 10168330
    Abstract: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 1, 2019
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. Iyer, Joseph Ralph Hermann, Michael B. Roof, Eric Martin Vaughn, Merrill Lynn Schaeffer
  • Publication number: 20180344835
    Abstract: The present invention relates to an immunogen-carrier, wherein the immunogen-carrier is preferably a virus-like particle (VLP) composed of a plurality of a modified PCV2 ORF2 protein. In particular, the present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a compliance marker for vaccines including a subunit antigen, and a DIVA (Differentiating Infected from Vaccinated Animals) system which makes it possible to differentiate between animals infected with a pathogen and animals treated with a subunit antigen derived from said pathogen.
    Type: Application
    Filed: March 29, 2016
    Publication date: December 6, 2018
    Inventors: Luis Alejandro HERNANDEZ, Eric Martin VAUGHN
  • Patent number: 10131696
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Publication number: 20180289795
    Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 11, 2018
    Inventors: Marc Allan EICHMEYER, Wesley Scott JOHNSON, Eric Martin VAUGHN, Michelle L. WALZ
  • Patent number: 10039821
    Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: August 7, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
  • Publication number: 20180207260
    Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 26, 2018
    Inventors: Luis Alejandro HERNANDEZ, Arun V. IYER, Dianna M. Murphy JORDAN, Abby Rae PATTERSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA
  • Patent number: 10029005
    Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: July 24, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Marc Allan Eichmeyer, Wesley Scott Johnson, Eric Martin Vaughn, Michelle L. Walz